EI
CBAY

EAM Investors’s Cymabay Therapeutics CBAY Stock Holding History

EAM Investors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-207,152
Closed -$4.89M – 349
2023
Q4 		$4.89M Sell
207,152
-174,412
-46% -$3.11M 0.87% 7
2023
Q3 		$5.69M Buy
381,564
+8,940
+2% +$119K 1.1% 2
2023
Q2 		$4.08M Buy
372,624
+56,030
+18% +$522K 0.76% 13
2023
Q1 		$2.76M Sell
316,594
-233,876
-42% -$1.87M 0.54% 53
2022
Q4 		$3.45M Buy
550,470
+210,692
+62% +$801K 0.71% 18
2022
Q3 		$1.19M Buy
+339,778
New +$1.22M 0.26% 171
2020
Q4 		– Sell
-354,337
Closed -$2.56M – 412
2020
Q3 		$2.56M Buy
+354,337
New +$1.89M 0.61% 33
2018
Q3 		– Sell
-96,188
Closed -$1.29M – 385
2018
Q2 		$1.29M Sell
96,188
-237,549
-71% -$2.97M 0.2% 177
2018
Q1 		$4.33M Sell
333,737
-100,076
-23% -$1.24M 0.72% 15
2017
Q4 		$3.99M Sell
433,813
-160,191
-27% -$1.37M 0.71% 14
2017
Q3 		$4.79M Buy
+594,004
New +$4.02M 0.64% 32

Other funds holding CBAY

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

EAM Investors's CBAY Position: Q1 2024 in Review

EAM Investors sold out of Cymabay Therapeutics (CBAY) in Q1 2024, closing a stake of 207,152 shares — an estimated $4.89M sold.

EAM Investors first reported a position in CBAY in Q3 2017 and held it in 11 quarters. The position peaked at $5.69M in Q3 2023. 1 fund tracked by Wall St. Rank holds CBAY as of Q1 2024.

  • EAM Investors reported no remaining Cymabay Therapeutics position as of Q1 2024 after selling out during the quarter.
  • EAM Investors sold 207,152 Cymabay Therapeutics shares in Q1 2024, an estimated $4.89M.
  • EAM Investors first reported a position in Cymabay Therapeutics in Q3 2017 and held it in 11 quarters.
  • EAM Investors's Cymabay Therapeutics position peaked at $5.69M in Q3 2023.
  • 1 fund tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2024.

Based on EAM Investors's 13F filing for Q1 2024, filed 13 May 2024.